Recent research have focused on the intersection of GLP|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and dopamine neurotransmission. While GLP activators are increasingly employed for treating type 2 T2DM, their potential consequences on motivation circuits, specifically